Four things to know:
1. The acquisition was an all-stock transaction of roughly $109 million in value on the date prior to closing.
2. In the deal, Misonix acquired TheraSkin, Solys Medical’s cellular and tissue-based wound treatment.
3. The acquisition consisted of the issuance of around 5.7 million new shares to former Solys unitholders.
4. Misonix assumed Solsys’ outstanding secured debt of roughly $24 million.
More articles on devices:
Dr. Isaac Karikari: Changing attitudes toward opioids and how physicians can drive change
Dr. Timothy Kremchek to operate on Reds rookie Nick Senzel — 4 insights
Icotec to introduce new pedicle screw system — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.